Fed. Circ. Panel Walks Back $235M Skinny Label Ruling
By Dani Kass ( February 9, 2021, 11:44 AM EST) -- A Federal Circuit panel on Tuesday vacated its October finding that Teva induced infringement of a patent covering GlaxoSmithKline's drug Coreg to the tune of $235 million and set a new round of oral arguments in the high-profile fight over so-called skinny labels....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.